Budesonide, fluticasone propionate, and azithromycin do not modulate the membrane vesicle release by THP-1 macrophages and respiratory pathogens during macrophage infection

Charlotte Volgers1 · Gert E. Grauls1 · Pauline H. M. Hellebrand1 · Paul H. M. Savelkoul1,2 · Frank R. M. Stassen1

Received: 14 March 2017/Accepted: 5 May 2017/Published online: 20 May 2017 © The Author(s) 2017. This article is an open access publication

Abstract Patients with more severe chronic obstructive pulmonary disease frequently experience exacerbations and it is estimated that up to 50% of these exacerbations are associated with bacterial infections. The mainstay treatment for these infection-related exacerbations constitutes the administration of glucocorticoids, alone or in combination with antibiotics. A recent line of evidence demonstrates that many hormones including the steroid beclomethasone can also directly affect bacterial growth, virulence, and antibiotic resistance. The effect of these regimens on the release of potentially virulent and toxic membrane vesicles (MVs) is at present unclear. In this study, we determined the effect of several pharmacological agents on MVs release by and bacterial growth of common respiratory pathogens. We found that neither the release of MVs nor the bacterial growth was affected by the glucocorticoids budesonide and fluticasone. The macrolide antibiotic azithromycin only inhibited the growth of *Moraxella catarrhalis* but no effects were observed on bacterial MV release at a concentration that is achieved locally in the epithelial lining on administration. The macrophage pro-inflammatory response to MVs was significantly reduced after treatment with budesonide and fluticasone but not by azithromycin treatment. Our findings suggest that these glucocorticoids may have a positive effect on infection-related inflammation although the bacterial growth and MV release remained unaffected.

Keywords Membrane vesicles · Bacterial infection · Budesonide · Fluticasone propionate · Azithromycin · Non-typeable *Haemophilus influenzae* · *Moraxella catarrhalis* · *Streptococcus pneumoniae* · *Pseudomonas aeruginosa*

Introduction Chronic obstructive pulmonary disease (COPD) is a progressive airway disease that is characterized by excessive inflammation resulting in airway limitation and a progressive decline in lung function (Barnes 2008). Moreover, patients with moderate and severe disease often experience exacerbations of disease (O’Reilly et al. 2006). These exacerbations are frequently triggered by infectious insults and it has been estimated that bacterial infections account for up to 50% of the exacerbations (Sethi and Murphy 2008).

Standard treatment of patients that experience an exacerbation consists of the administration of systemic corticoids alone or combined with antibiotics (Walters et al. 2009; Laue et al. 2015; Ram et al. 2016). Moreover, it has been shown in several large randomized trials that patients with stable disease may benefit from the use of inhaled corticosteroids (ICS) and antibiotics as these can reduce the number of exacerbations (Donath et al. 2013; Han et al. 2014; Kew et al. 2014). Apart from their antibacterial effects, macrolide antibiotics also have been shown to reduce inflammation (Čulić et al. 2001; Brusselle and Joos 2014). ICS, on the other hand, may have
controversial effects on the defence against bacteria. Although they are able to reduce epithelial invasion by airway pathogens, this might be at the expense of resistance to infections as ICS also inhibit the release of antimicrobial peptides and suppress inflammatory processes (Mitchell et al. 2007; Barbier et al. 2008; Wang et al. 2013). Alternatively, ICS may also have a direct effect on the bacteria as recent studies have shown that hormones such as catecholamines and steroid hormones can also directly affect bacterial growth, virulence, and gene expression (Freestone et al. 2013; Earl et al. 2015).

Bacterial membrane vesicles (MVs) are released by bacteria in response to a variety of stressors. These nanosized (30–300 nm) MVs do not only contribute to bacterial virulence, but also increase the resistance to certain antimicrobial peptides and antibiotics. Moreover, they can exert strong pro-inflammatory responses (Schwechheimer et al. 2014; Kaparakis-Liaskos and Ferrero 2015). Therefore, understanding bacterial behavior in terms vesiculation may help to improve treatment strategies. Moreover, host cells are also known to release MVs (Koifman et al. 2017), and several pro-inflammatory properties have been assigned to MVs released in the context of infection and inflammation (Yáñez-Mó et al. 2015; Schorey and Harding 2016).

In this study, we aimed to address if treatment with the glucocorticoids budesonide and fluticasone and the antibiotic azithromycin (a) affects MV release by bacteria and macrophages, and (b) suppresses the pro-inflammatory response to these MVs released by several common respiratory bacterial pathogens.

**Materials and methods**

**Reagents and antibodies**

Budesonide (BUD), fluticasone propionate (FLUT), and azithromycin (AZI) were from Sigma (Sigma Aldrich, St. Louis, MO, USA). The anti-*Haemophilus influenzae* type b (α-Hib; clone 1079/457) monoclonal antibody was obtained from Acris (Acris GmbH, Herford, Germany). The rabbit serum against *Moraxella catarrhalis* (Mrc) isolate (University Medical Centre Maastricht (MUMC+), the Netherlands). The ATCC strains were well characterized and recommended by ATCC for quality control and antimicrobial susceptibility testing. All bacteria were cultured overnight on blood plates except for NTHi which was cultured on vitalex-supplemented chocolate agar plates (Oxoid, Wesel, Germany) in 5% CO₂ at 37 °C. After overnight pre-culture, bacteria were resuspended at 0.5 McFarland (1.5 × 10⁸ colony forming units (cfu)/ml) in RPMI1640 and used for infection or culture experiments. For bacterial culture, bacteria were used at 5 × 10⁷ cfu/ml and culture without or with BUD, FLUT, or AZI for 6 h in 10 ml RPMI1640. Next, the conditioned media were processed by centrifugation at 1200g for 10 min, at room temperature. The pelleted bacteria were washed, diluted in PBS, and the optical density was determined at 600 nm using optical methacrylate disposable cuvettes (Sarstedt, Newton, NC, USA). The supernatants were centrifuged again at 1200g for 10 min, and the supernatants were filtered through 0.22 μm filters. Hereafter, the supernatants were further concentrated 20 times to a total of 500 μl by centrifugation at 4000g for 15 min using Amicon Ultra-15 10-kDa centrifugal filter units (Millipore, Billerica, MA, USA).

For bacterial culture, bacteria were used at 10⁷ cfu/ml following culturing for 4 h in 30 ml complete vesicle-depleted medium containing 5% FCS, that was obtained as described in the “Cells and media” section. Upon culture, supernatants were depleted from bacteria by two centrifugation steps at 1200g for 10 min and 0.22 μm filtration. The supernatants that were cleared from bacteria were then further processed by ultrafiltration and size-exclusion chromatography (SEC), as described below.

**Cells and media**

The human monocytic cell line THP-1 (ATCC-TIB202) was maintained in RPMI1640 (Sigma, St. Louis, MO, USA). Purification of antibodies from serum was performed using the antibody serum purification kit based on protein A (Abcam, Cambridge, MA, USA). Antibodies for detection for flow cytometric analyses were PE-conjugated using a PE-labeling kit from Abcam according to the manufacturers’ instructions (Cambridge, MA, USA).
USA) supplemented with 100 mM sodium pyruvate, 22.5% glucose, 25 mM β-mercaptoethanol, and 10% fetal calf serum (FCS) (Lonza, Verviers, Belgium) and cultured in 5% CO₂ at 37 °C. For monocyte differentiation, cells were seeded in a 24-well plate at 0.5 × 10⁵ cells/well or in a 96-well plate at 1 × 10⁴ cells/well and stimulated for 72 h with 200 nM phorbol 12-myristate 13-acetate (PMA; Sigma, St. Louis, MO, USA). THP-1 macrophage stimulations were performed in vesicle-depleted medium containing 5% FCS (complete vesicle-depleted medium). This medium was obtained by combining vesicle-depleted RPMI1640 medium with 30% FCS with FCS-free medium (both supplemented with sodium pyruvate and glucose). Vesicle-depleted medium was generated by overnight centrifugation at 100,000 g using a 70Ti-rotor, κ-factor 44 in an Optima L-90 K ultracentrifuge (both Beckman Coulter, Fullerton, CA, USA).

Macrophage infection for membrane vesicle analysis

THP-1 macrophages seeded in 24-well plates were washed three times with PBS, and medium was replaced with complete vesicle-depleted medium. Hereafter, the cells were pre-treated with BUD (0.1 μM), FLUT (0.1 μM), or AZI (3 μg/ml) for 1 h, and the concentrations were previously calculated to represent a concentration as can be obtained locally upon administration by inhalation (Wagner et al. 2015; Olsen et al. 1996; Ek et al. 1999). After pretreatment, macrophages were infected with one of the bacteria at a multiplicity of infection of ten for 6 h. After infection, the medium was harvested, processed by centrifugation at 300×g and 1200×g, filtrated with a 0.22-μm micropore filter, and subsequently analyzed by flow cytometry.

MV concentration and purification from conditioned medium using ultrafiltration and SEC

The bacteria-cleared conditioned media obtained from bacterial cultures were subjected to ultrafiltration (Lobb et al. 2015) and SEC (Boing et al. 2014). First, the cleared conditioned media were concentrated to 500 μl in 2 runs at 4000×g for 15 min at room temperature using Amicon Ultra-15 10-kDa centrifugal filter units (Millipore, Billerica, MA, USA) (Lobb et al. 2015). Then, the concentrates were purified by SEC using Sephacryl columns as described by Boing et al. with minor modifications (Boing et al. 2014). For this, a 15-ml TELOS filtration column (Kinesis Scientific Experts, St. Neots, Cambridgeshire, UK) was loaded onto the column and fractions of 0.5 ml were eluted using PBS. The fractions that were found to be highly enriched for MVs and negative for free protein (fractions 7–11 as were determined by flow cytometry and Micro BCA, Pierce, Rockford, IL, USA) were pooled and stored at −80 °C until further use.

Flow cytometric analysis of MVs using antibody-coated latex beads

A bead-based flow cytometric assay based on a method that was previously described by Volgers et al. (2017) was used for the semi-quantitative analysis of bacterial MVs and CD63+/CD81+ host cell-derived MVs. Four-micrometer-sized aldehyde–sulfate beads were washed in MES buffer, coated with α-CD63 antibody, or antibodies directed against bacterial vesicles (with the exception of Spn as we could not establish this assay for Spn). Antibody-coated beads were incubated overnight with processed supernatants (200 μl) obtained after infection under constant agitation at 1000 rpm at room temperature. Next, the beads were washed twice with PBS filtered through a 0.22-μm filter containing 2% (w/v) bovine serum albumin (BSA) and incubated with PE-conjugated detection antibodies (α-CD81-PE for host cell vesicles or an PE-conjugated α-bacterial antibody) for 90 min under continuous agitation at room temperature. Bacterial antibodies were PE-conjugated using a PE-conjugation kit (Abcam, Cambridge, MA, USA) according to the manufacturer’s instructions. Then, the vesicle-bead complexes were washed, suspended in PBS (300 μl), and used for flow cytometric analysis using a FACSCanto™ (BD Bioscience, Franklin Lakes, NJ, USA). The lower threshold for detection was set at 2% based on the percentage of PE-positive control beads (based on culture medium). Analyses were performed using FACSDiva Software. The relative amount of MVs was calculated by the multiplication of the percentage of positive beads with the median fluorescence intensity and expressed relative to the control (as % of control).

MV analysis by tunable resistive pulse sensing

Tunable resistive pulse sensing analysis was used to determine the MV-concentration using the qNano Gold, the Izon Control Suite Software v3.2, and the reagent kit (type RK1) for EV analysis from Izon (Izon Science Ltd., Oxford, UK). The measurements were performed using a NP150-pore. The stretch was fixed at 47 mm, the pressure kept at 6 mbar, and a baseline current of ±100 nA was maintained. Solution G was added (10%) to supernatants that were diluted in solution Q (1:1), and each sample was measured for 10 min and measurements were repeated when system instabilities occurred. The samples were calibrated using 114-nm polystyrene calibration beads.
(CPC100, Izon Science Ltd., Oxford, UK) at a concentration of $1 \times 10^9$ particles/ml diluted in culture medium.

**Macrophage stimulation with MVs**

Stimulation of THP-1 macrophages with MVs was performed using macrophages seeded in 96-well plates. Prior to stimulation, the cells were washed three times with PBS whereafter the medium was replaced with complete vesicle-depleted medium. Then the cells were pre-treated with BUD (0.1 μM), FLUT (0.1 μM), or AZI (3 μg/ml) for 1 h. Next, the cells were washed again after which they were exposed to 20 μl of the MV-containing SEC fractions, without or in the presence of BUD, FLUT, or AZI, in complete vesicle-depleted medium for 16 h. Hereafter, the culture supernatants were harvested and used for cytokine measurements.

**Cytokine measurements**

TNF-α levels in the supernatants from the stimulation experiments were determined by enzyme-linked immunosorbent assay (ELISA) using the human Ready-Set-Go TNF-α ELISA kit eBioscience (Affymetrix eBioscience, Santa Clara, CA, USA).

**Statistical analysis**

Statistical analysis was performed using GraphPad Prism 5 Software (GraphPad, San Diego, CA, USA). Statistical dispersion was determined by calculating the standard error of the mean. A Mann–Whitney test was performed for the statistical analysis of the variance between the means of two groups. $P$ values were considered significant when $<0.05$.

**Results**

**Effect of BUD, FLUT, and AZI on bacterial and host cell membrane vesicle release during infection**

First, the effect of BUD, FLUT, and AZI on bacterial MV release was determined. This was done semi-quantitatively by flow cytometry based on antibody-coated beads. We found that neither FLUT nor BUD significantly affected the vesicle release by NTHi and Mrc (Fig. 1a, b). Treatment with AZI also did not affect the MV release (Fig. 1c).

The release of MVs is highly conserved and apart from the bacteria the host cells are also known to release
membrane vesicles. We therefore assessed the effect of BUD, FLUT, and AZI treatment on the release of CD63+/CD81+ host cell vesicles by macrophages under control conditions and upon infection. Neither treatment with BUD and FLUT, nor that with AZI, was found to affect the release of host cell MVs (Fig. 2).

**Bacterial MV release in response to BUD, FLUT, and AZI**

Next, we aimed to determine how the bacterial MV release is affected by BUD, FLUT, and AZI in the absence of host cells. Vesicle release after 6 h of culture without or with these drugs was determined by tunable resistive pulse sensing analysis. We observed that treatment with neither FLUT, BUD, nor AZI affected the release of bacterial MVs (Fig. 3a).

Next, we determined if FLUT, BUD, or AZI had any effect on the bacterial growth. To assess this, the relative number of bacteria was determined upon treatment with FLUT, BUD, and AZI, which was done by measuring the optical density. As shown in Fig. 3b, only the Mrc counts were significantly reduced after bacterial culture in the presence of AZI.

**Effect of BUD, FLUT, and AZI on the TNF-α response to immuno-stimulatory bacterial membrane vesicles**

Since bacterial MVs can possess a strong pro-inflammatory character (Macdonald 2013; Ellis and Kuehn 2010; Schaar et al. 2011a; Ren et al. 2012; Olaya-Abriol et al. 2014), our next aim was to establish if BUD, FLUT, and AZI affected the TNF-α release by naïve macrophages in response to bacteria membrane vesicles. MVs from both NTHi and Mrc induced the release of TNF-α by macrophages, while the response to MVs from Psao and Spn was less pronounced. Treatment with BUD and FLUT significantly reduced the release of TNF-α by macrophages in response to bacterial MVs from NTHi and Mrc (Fig. 4a, b). In contrast, the TNF-α release in response to Spn and Psao MVs was not affected by BUD or FLUT. No significant effect of AZI was found on the TNF-α response to either NTHi-, Mrc-, Spn-, or Psao-derived MVs (Fig. 4c).

**Discussion**

In this study, we determined if the glucocorticoids budesonide (BUD) and fluticasone propionate (FLUT), and the antibiotic azithromycin (AZI) affected the release of bacterial MVs. Results demonstrated that neither the release of bacterial nor host cell vesicles was altered by any of the drugs. Moreover, except for Mrc, whose growth was significantly reduced by AZI, bacterial growth was not affected by any of the drugs. In contrast, the release of...
TNF-α by vesicle-stimulated macrophages was significantly reduced by the glucocorticoids, but not by AZI.

Recently it has been shown that non-typeable *H. influenzae* exposure to the glucocorticoid beclomethasone results in a phenotype that resembles the *RpoE* knock-out phenotype, and is characterized by an enhanced antibiotic resistance and biofilm formation (Earl et al. 2015). The activation of this *RpoE* gene, which is part of the σ^E^ stress response pathway, has been associated with the release of MVs by Gram-negative bacteria (Schwechheimer et al. 2014). This inspired us to hypothesize that glucocorticoids might inhibit the release of bacterial MVs. However, we found that neither FLUT nor BUD at concentrations that can be attained locally on inhalation affected the release of bacterial MVs.

Moreover, several antibiotics have also been shown to induce the release of bacterial MVs (Hakenbeck et al. 1983; Kadurugamuwa and Beveridge 1995; Schaar et al. 2011b). In our hands, however, AZI at a concentration that is achieved locally in vivo on treatment did not affect the MV release, neither during infection nor in culture. Remarkably, only the bacterial growth of Mrc was significantly reduced by AZI. We also anticipated that the growth of NTHi and Spn would have been inhibited since the minimum inhibitory concentrations (MICs), which were determined for these bacteria using azithromycin sensitivity testing strips, are far below the AZI

---

**Fig. 3** Effect of BUD, FLUT, and AZI on the MV release and bacterial growth during culture. NTHi, Mrc, Spn, or Psa were cultured for 6 h in the continuous presence of FLUT, BUD, or AZI. MV release was determined by TRPS analysis (a) and the bacterial growth was determined with the optical density of the bacterial suspensions at 600 nm (b) (n = 3, *P < 0.05)

---

**Fig. 4** Effect of FLUT, BUD, and AZI on the TNF-α release by naïve macrophages in response to bacteria MVs. Macrophages were pre-treated for 1 h with FLUT (a), BUD (b), or AZI (c), before they were exposed overnight to purified MVs released during culture of NTHi, Mrc, Spn, or Psa. The TNF-α release was determined by ELISA (n = 4, *P < 0.05)
concentration used in our experiments: NTHi: 0.125; Mrc: 0.125, Spn: 1.5 μg/mL. For Psa, we obtained a MIC of 12 μg/ml which may explain why no reduced bacterial numbers were observed on AZI treatment of Psa. These results were also consistent with previously reported MIC values for NTHi (0.25–4 μg/ml), Mrc (0.25–0.5 μg/ml), and 8–512 μg/ml for Psa but not for Spn (0.25–0.5 μg/ml) (Leclercq et al. 2013; Imperi et al. 2014). The reason for this discrepancy remains unclear as it has been shown that azithromycin can be bactericidal already at early time points (Drago et al. 2005). As it has been shown previously that MVs can contribute to the resistance against certain antibiotics (Schwechheimer and Kuehn 2015), it will be interesting to determine whether MVs participate in the increased azithromycin resistance.

As these drugs are known for their immunosuppressive properties, we additionally determined their effects on the release of TNF-α by naïve macrophages in response to bacterial MVs. We found that both budesonide and fluticasone inhibited the membrane vesicle-induced TNF-α release. This was in line with previous studies that demonstrated that BUD and FLUT have anti-inflammatory properties (Khair et al. 1994; Fattal-German et al. 1996; Ek et al. 1999; Brusselle and Joos 2014). Although some studies have acknowledged an anti-inflammatory effect to AZI (Čulić et al. 2001; Brusselle and Joos 2014), we did not observe a reduced pro-inflammatory response to bacterial MVs after AZI treatment.

It should be noted that in our studies we used a THP-1 macrophage cell model. These PMA-differentiated THP-1 cells show a high similarity with monocyte-derived macrophages both in morphology and behavior (Daigneault et al. 2010). Yet, it cannot be excluded that their responsiveness regarding MV release following infection might be different from alveolar macrophages whose phenotype might be slightly different because of differences in the local micro-environment (Hussell and Bell 2014). Several studies indicate that the release of MVs in response to an inflammatory stimulus (i.e., LPS) occurs in a similar fashion by THP-1 and by alveolar macrophages (Eltom et al. 2014; Soni et al. 2016); however, alveolar macrophages should be used in future studies before definite conclusions on the vesicle release in the context of infection can be drawn. Moreover, we did not determine the effects of BUD, FLUT, and AZI on the release of vesicles under more physiologically relevant conditions, i.e., in the presence of pro-inflammatory mediators or during cigarette smoke exposure. It cannot be excluded that these conditions affect the sensitivity to treatment. Finally, this study only quantified the MVs on treatment with BUD, FLUT, or AZI, but did not characterize the MVs. Vesicle characterization may reveal whether these agents are able to affect the composition and thereby possibly the physiological aspects of these vesicles. Therefore, this may be a subject for further investigation.

To conclude, glucocorticoids and antibiotics are frequently prescribed to treat COPD patients in particular during an exacerbation (Walters et al. 2009; Laue et al. 2015; Ram et al. 2016). Treatment with glucocorticoids is considered an effective treatment for COPD patients that experience an exacerbation, as it increases the rate of lung function improvement and treatment success mostly because it significantly reduces local inflammation (Walters et al. 2009; Jen et al. 2012). Regarding the use of antibiotics, up to 50% of all exacerbations are associated with bacterial infections (Wilkinson et al. 2006; Hurst et al. 2006; Papi et al. 2006; Bafadhel et al. 2011). Therefore, this study aimed to determine how these drugs affect several aspects that to some extent may determine the course of infection: the bacterial growth, vesicle release, and pro-inflammatory response to these MVs. Our study shows that the bacterial growth and MVs release are not affected by FLUT, BUD, or AZI treatment. Treatment with FLUT and BUD, however, was efficient to reduce the pro-inflammatory response to bacterial MVs. The implications of these findings with respect to the effects of these glucocorticoids on airway inflammation and on the resolution of infection need to be further investigated.

Acknowledgements The authors wish to thank dr. J. P. Hays from the Erasmus University Medical Centre (Erasmus MC), Rotterdam, the Netherlands, for kindly providing the rabbit antisera to Moraxella catarrhalis used in this publication.

Compliance with ethical standards

Funding information This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Bafadhel M, McKenna S, Terry S et al (2011) Acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 184:662–671. doi:10.1164/rccm.201104-0597OC

Barbier M, Agusti A, Alberti S (2008) Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 32:1283–1288. doi:10.1183/09031936.00020608

Barnes PJ (2008) Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8:183–192. doi:10.1038/nri2254
Böing AN, van der Pol E, Grootemaat AE et al (2014) Single-step isolation of extracellular vesicles by size-exclusion chromatography. J Extracell Vesicles 3:23430. doi: 10.3402/jev.v3.23430

Brusselle GG, Joos G (2014) Is there a role for macrolides in severe asthma? Curr Opin Pulm Med 20:95–102. doi: 10.1097/MCP.000000000000017

Čulić O, Eraković V, Parnham MJ (2001) Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 429:209–229. doi: 10.1016/S0014-2999(01)01321-8

Daigneault M, Preston JA, Marriott HM, Whyte MKB, Dockrell DH (2010) The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One 5. doi: 10.1371/journal.pone.0008668

Donath E, Chaudhry A, Hernandez-Aya LF, Lit L (2013) A meta-analysis on the pro-inflammatory use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease. Respir Med 107:1385–1392. doi:10.1016/j.rmed.2013.05.004

Drago L, De Vecchi E, Nicola L et al (2005) Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens. APMIS 113:655–663. doi: 10.1111/j.1600-0463.2005.apm_195.x

Earl CS, Keong TW, An S et al (2015) Haemophilus influenzae responds to glucocorticoids used in asthma therapy by modulation of biofilm formation and antibiotic resistance. EMBO Mol Med 7:1018–1033. doi:10.15252/emmm.201505088

Ek A, Larsson K, Siirjul M, Palmberg L (1999) Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 54:691–699. doi: 10.1034/j.1398-9995.1999.00087.x

Ellis TN, Kuehn MJ (2010) Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev 74:81–94. doi: 10.1128/MMBR.00301-09

Eltom S, Dale N, Raemdonck KR et al (2014) Respiratory infections cause the release of extracellular vesicles: implications in exacerbation of asthma/COPD. PLoS One 9:e101087. doi: 10.3389/fmicb.2014.00178

Fattal-German M, Le Roy Ladurie F, Lecerf F, Berrih-Aknin S (1996) Characterization of protective extracellular membrane-derived vesicles produced by Pseudomonas aeruginosa outer membrane vesicles carry membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion. J Bacteriol 177:3998–4008

Kaparakis-Liaskos M, Ferrero RL (2015) Immune modulation by bacterial outer membrane vesicles. Nat Rev Immunol 15:375–387. doi: 10.1038/nri3837

Kew KM, Dias S, Cates CJ (2014) Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database of Systematic Reviews. CD010844. doi:10.1002/14651858.CD010844.pub2

Khair OA, Devalia JL, Abdelaziz MM et al (1994) Effect of Haemophilus influenzae endotoxin on the synthesis of IL-6, IL-8, TNF-alpha and expression of ICAM-1 in cultured human bronchial epithelial cells. Eur Respir J 7:2199–2116

Koifman N, Biran I, Aharon A et al (2017) A direct-imaging cryo-EM study of shedding extracellular vesicles from leukemic monocytes. J Struct Biol. doi: 10.1016/j.jsb.2017.02.004

Laue J, Reiert E, Melbye H (2015) When should acute exacerbations of COPD be treated with systemic corticosteroids and antibiotics in primary care: a systematic review of current COPD guidelines. NPJ Prim Care Respir Med 25:15002. doi: 10.1038/npjpcrm.2015.2

Leclercq R, Cantón R, Brown DJF et al (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141–160. doi: 10.1111/j.1469-0691.2011.03703.x

Lobb RJ, Becker M, Wen SW et al (2015) Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles 1:1–11. doi:10.3402/jev.v4.27031

Macdonald IA, Kuehn MJ (2013) Stress-induced outer membrane vesicle production by Pseudomonasaeruginosa. J Bacteriol 195:2971–2981. doi: 10.1128/JB.00267-12

Mitchell GB, Al-Haddawi MH, Clark ME et al (2007) Effect of corticosteroids and neuropeptides on the expression of defensins in bovine tracheal epithelial cells. Infect Immun 75:1325–1334. doi:10.1128/IAI.00686-06

O’Reilly JF, Williams AE, Holt K, Rice L (2006) Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J 15:346–353. doi:10.1016/j.pcrj.2006.08.009

Olaya-Abril A, Prados-Rosales R, McConnell MJ et al (2014) Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae. J Proteomics 106:46–60. doi:10.1016/j.jprot.2014.04.023

Olsen KM, San Pedro G, Ganss CA et al (1996) Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 40:2582–2585

Papi A, Bellettato CM, Braccioni F et al (2006) Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 173:1114–1121. doi:10.1164/rcrm.200506-859OC

Ram FS, Rodriguez-Roisin R, Granados-Navarrete A et al (2016) Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. doi:10.1002/14651858.CD004403.pub2.Copyright

Ren D, Nelson KL, Uchakin PN, Smith AL, Gu X-X, Daines DA et al (2012) Characterization of extended co-culture of non-typeable Haemophilus influenzae with primary human respiratory tissues. Exp Biol Med 237:540–547. doi:10.1258/ebm.2011.0113711377

Schaar V, De Vries SPW, Perez Vidakovics MLA et al (2011a) Multicomponent Moraxella catarrhalis outer membrane vesicles induce an inflammatory response and are internalized by human epithelial cells. Cell Microbiol 13:432–449. doi:10.1111/j.1462-5822.2010.01546.x

Schaar V, Nordström T, Mörgelin M, Riesbeck K (2011b) Moraxella catarrhalis outer membrane vesicles carry β-lactamase and...
promote survival of *Streptococcus pneumoniae* and *Haemophilus influenzae* by inactivating amoxicillin. Antimicrob Agents Chemother 55:3845–3853. doi:10.1128/AAC.01772-10

Schorey JS, Harding CV (2016) Extracellular vesicles and infectious diseases: new complexity to an old story. J Clin Invest 2016(126):1181–1189. doi:10.1172/JCI81132

Schwechheimer C, Kuehn MJ (2015) Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol 13:605–619. doi:10.1038/nrmicro3525

Schwechheimer C, Kulp A, Kuehn MJ et al (2014) Modulation of bacterial outer membrane vesicle production by envelope structure and content. BMC Microbiol 14:324. doi:10.1186/s12866-014-0324-1

Sethi S, Murphy TF (2008) Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359:2355–2365. doi:10.1056/NEJMra0800353

Soni S, Wilson MR, O’Dea KP et al (2016) Alveolar macrophage-derived microvesicles mediate acute lung injury. Thorax. doi:10.1136/thoraxjnl-2015-208032

Volgers C, Benedikter BJ, Grauls GE et al (2017) Bead-based flow-cytometry for semi-quantitative analysis of complex membrane vesicle populations released by bacteria and host cells. Microbiol Res 200:25–32. doi:10.1016/j.microres.2017.04.003

Wagner C, Goldmann T, Rohmann K, Rupp J, Marwitz S, Loria JR detto, et al (2015) Budesonide Inhibits Intracellular Infection with Non-Typeable Haemophilus influenzae despite Its Anti-Inflammatory Effects in Respiratory Cells and Human Lung Tissue: A Role for p38 MAP Kinase. Respiration 90:416–425. doi:10.1159/000439226

Walters JA, Gibson PG, Wood-Baker R et al (2009) Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane database Syst Rev. doi:10.1002/14651858.CD001288.pub3

Wang P, Wang X, Yang X et al (2013) Budesonide suppresses pulmonary antibacterial host defense by down-regulating cathelicidin-related antimicrobial peptide in allergic inflammation mice and in lung epithelial cells. BMC Immunol 14:7. doi:10.1186/1471-2172-14-7

Wilkinson TMA, Hurst JR, Perera WR et al (2006) Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 129:317–324. doi:10.1378/chest.129.2.317

Yáñez-Mó M, Siljander PR-M, Andreu Z, Bedina Zavec A, Borriàs F, Editl B, et al (2015) Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 4:27066. doi:10.3402/jev.v4.27066